ASLN ASLAN Pharmaceuticals Limited

4.35
-0.42  -9%
Previous Close 4.77
Open 4.99
Price To Book 3.37
Market Cap 139416630
Shares 32,049,800
Volume 8,376
Short Ratio
Av. Daily Volume 10,865

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal data due 2019.
Varlitinib - TREETOP
Biliary tract cancer
Phase 2 data due 4Q 2018.
Varlitinib
Gastric cancer
Phase 1/2 interim data due 4Q 2018.
Varlitinib
Gastric cancer
Phase 2 interim data presented at ASH December 2018 - noted 4/8 patients showed signs of efficacy.
ASLAN002
Acute Myeloid Leukemia (AML)
Phase 1/2 new data to be presented at at ASCO Gastrointestinal Cancers Symposium January 18, 2019 11:30 AM.
Varlitinib + gemcitabine and cisplatin
Biliary tract cancer